Edema control by cediranib, a vascular endothelial growth factor receptor - Targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

Journal of Clinical Oncology

Volumn 27, Issue 15, 2009, Pages 2542-2552

  Kamoun, Walid S ^b   Ley, Carsten D ^b   Farrar, Christian T ^b   Duyverman, Annique M ^b   Lahdenranta, Johanna ^b   Lacorre, Delphine A ^b   Batchelor, Tracy T ^b   Di Tomaso, Emmanuelle ^b   Duda, Dan G ^b   Munn, Lance L ^b   Fukumura, Dai ^b   Gregory Sorensen, A ^b   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CEDIRANIB; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 4; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; BRAIN TUMOR; CANCER CELL; CELL PROLIFERATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRY WEIGHT; GLIOBLASTOMA; MACROPHAGE; MICROSCOPY; MONOTHERAPY; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; VASCULAR TUMOR; VASCULARIZATION; WATER CONTENT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN EDEMA; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66349121063     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.9356     Document Type: Article

References (26)

1. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007 (Pubitemid 46075199)
2. Cloughesy TF: A phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:91s, 2008 (suppl; abstr 2010b)
3. Pope WB, Lai A, Nghiemphu P, et al: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260, 2006 (Pubitemid 43739717)
4. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007 (Pubitemid 46424067)
5. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787, 2008
6. Sorensen AG, Batchelor TT, Wen PY, et al: Response criteria for glioma. Nat Clin Pract Oncol 5:634-644, 2008
7. Yuan F, Salehi HA, Boucher Y, et al: Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54:4564-4568, 1994 (Pubitemid 24276471)
8. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005 (Pubitemid 40775678)
9. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999 (Pubitemid 29463104)
10. Brown EB, Campbell RB, Tsuzuki Y, et al: In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 7:864-868, 2001
11. Tyrrell JA, di Tomaso E, Fuja D, et al: Robust 3-D modeling of vasculature imagery using superellipsoids. IEEE Trans Med Imaging 26:223-237, 2007 (Pubitemid 46362765)
12. Silbergeld D, Rostomily R, Alvord EJ: The cause of death in patients with glioblastoma is multifactorial: Clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol 10:179-185, 1991
13. Manley GT, Fujimura M, Ma T, et al: Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 6:159-163, 2000 (Pubitemid 30082359)
14. Thiagarajah JR, Papadopoulos MC, Verkman AS: Noninvasive early detection of brain edema in mice by near-infrared light scattering. J Neurosci Res 80:293-299, 2005
15. Papadopoulos MC, Manley GT, Krishna S, et al: Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 18:1291-1293, 2004 (Pubitemid 39561580)
16. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380, 2002
17. Fischer C, Jonckx B, Mazzone M, et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475, 2007 (Pubitemid 350007692)
18. Badruddoja MA, Krouwer HG, Rand SD, et al: Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol 5:235-243, 2003
19. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
20. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004 (Pubitemid 40017699)
21. Svensson A, Backman U, Fuchs D, et al: Angiogenesis can be reduced without significant reduction of tumor growth. Anticancer Res 27:3883-3889, 2007
22. Shojaei F, Ferrara N: Refractoriness to antivascular endothelial growth factor treatment: Role of myeloid cells. Cancer Res 68:5501-5504, 2008
23. Ebos JM, Lee CR, Christensen JG, et al: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 104:17069-17074, 2007
24. Shaked Y, Henke E, Roodhart JM, et al: Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273, 2008
25. Batchelor TT, di Tomaso E, Duda DG, et al: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. American Association for Cancer Research Annual Meeting, San Diego, CA, April 12-16, 2008 (abstr LB-247)
26. Padera TP, Kuo AH, Hoshida T, et al: Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 7:2272-2279, 2008